Literature DB >> 22857270

Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet.

Jolyon Mitchell1, Mark Copley, Yvonne Sizer, Theresa Russell, Derek Solomon.   

Abstract

BACKGROUND: The Abbreviated Impactor Measurement (AIM) concept simplifies determination of aerodynamic size metrics for inhaler quality control testing. A similar approach is needed to compare in vitro particle size distribution metrics with human respiratory tract (HRT) deposition.
METHODS: An abbreviated impactor based on the Andersen eight-stage cascade impactor (ACI) was developed having two size-fractionating stages with cut-points at 4.7 and 1.1 μm aerodynamic diameter at 28.3 L/min, to distinguish between coarse (CPM), fine (FPM), and extra-fine (EPM) mass fractions likely to deposit in the oropharynx, airways of the lungs, or be exhaled, respectively. In vitro data were determined for pressurized metered dose inhaler (pMDI)-delivered salbutamol (100 μg/actuation ex valve) with an "Alberta" idealized adult upper airway (throat) inlet (AIM-pHRT). Corresponding benchmark data for a full resolution Andersen eight-stage cascade impactor with "Alberta" idealized throat (ACI-AIT) and ACI-Ph.Eur./USP inlet were obtained with the same product.
RESULTS: Mass recoveries (μg/actuation; mean ± SD) were equivalent at 100.5 ± 0.7; 97.2 ± 4.9 and 101.5 ± 9.5 for the AIM-pHRT, ACI-AIT, and ACI-Ph.Eur./USP induction port, respectively [one-way analysis of variance (ANOVA), p=0.64]. Corresponding values of CPM were 59.2 ± 4.2; 58.4 ± 2.4, and 65.6 ± 5.8; the AIT captured larger particles more efficiently than the Ph.Eur./USP induction port, so that less large particle mass was apparent in the upper stages of the ACI-AIT (p ≤ 0.037). Equivalent values of FPM were similar regardless of inlet/abbreviation at 41.3 ± 4.2; 38.7 ± 3.0, and 35.9 ± 3.8 (p=0.054), and EPM measures (1.7 ± 0.3; 2.0 ± 0.5; 2.1 ± 0.3) were also comparable (p=0.32).
CONCLUSIONS: The AIT inlet significantly increased the capture of the coarse fraction compared with that collected by the Ph.Eur./USP induction port. Measures obtained using the AIM-pHRT apparatus were comparable with those obtained with the ACI-AIT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22857270     DOI: 10.1089/jamp.2011.0925

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  6 in total

1.  Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications.

Authors:  S C Nichols; J P Mitchell; C M Shelton; D L Roberts
Journal:  AAPS PharmSciTech       Date:  2013-01-24       Impact factor: 3.246

2.  Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.

Authors:  Susanne R Youngren-Ortiz; David B Hill; Peter R Hoffmann; Kenneth R Morris; Edward G Barrett; M Gregory Forest; Mahavir B Chougule
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-03-09       Impact factor: 2.849

3.  Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach.

Authors:  Poonam Sheth; Dennis Sandell; Denise S Conti; Jay T Holt; Anthony J Hickey; Bhawana Saluja
Journal:  AAPS J       Date:  2017-06-07       Impact factor: 4.009

Review 4.  Innovative preclinical models for pulmonary drug delivery research.

Authors:  Stephan Ehrmann; Otmar Schmid; Chantal Darquenne; Barbara Rothen-Rutishauser; Josue Sznitman; Lin Yang; Hana Barosova; Laurent Vecellio; Jolyon Mitchell; Nathalie Heuze-Vourc'h
Journal:  Expert Opin Drug Deliv       Date:  2020-02-23       Impact factor: 6.648

Review 5.  Repurposing drug molecules for new pulmonary therapeutic interventions.

Authors:  Piyush P Mehta; Vividha S Dhapte-Pawar
Journal:  Drug Deliv Transl Res       Date:  2020-11-13       Impact factor: 4.617

Review 6.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.